Alvotech (ALVO) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $3.27: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration,... Read more
Sell if holding. Engine safety override at $3.27: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 3.6/10, high confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 93d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Alvotech
Latest news
- What forecasting risk Alvotech (ALVO)? (-6.25%) 2026-04-29 - Chart Patterns - Newser — Newser negative
- What forecasting risk Alvotech (ALVO)? (-6.25%) 2026-04-29 - Momentum Signals - Newser — Newser negative
- Alvotech (ALVO) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Alvo Minerals Sets May 2026 AGM to Approve 2025 Accounts and Pay Report - TipRanks — TipRanks positive
- Alvotech (NASDAQ:ALVO) Announces Earnings Results - MarketBeat — MarketBeat neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Revenue shrinking — -20.2% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -14.4%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.27: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $3.07. Score 3.6/10, high confidence.
Take-profit target: $3.66 (+12.3% upside). Prior stop was $3.07. Stop-loss: $3.07.
DATA_ISSUE: analyst_target_implausible (raw $15.80 vs price $3.26 — ratio 4.8×). Rejected, falling back to technical TP.; Quality below floor (3.8 < 4.0).
Alvotech trades at a P/E of 33.1 (forward 37.3). TrendMatrix value score: 3.5/10. Verdict: Sell.
12 analysts cover ALVO with a consensus score of 3.9/5. Average price target: $16.
What does Alvotech do?Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers...
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.